title: Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease.
abstract: OBJECTIVE
  There is uncertainty about the efficacy and safety of treatment for hepatitis C virus (HCV) infection in patients with inflammatory bowel disease (IBD). IBD can become exacerbated during treatment with interferon (IFN), and serious adverse events, such as pancytopenia or hepatotoxicity, can be compounded by drug interactions. We investigated the risk of exacerbation of IBD during HCV therapy and the rate of adverse effects of concomitant therapy for HCV and IBD. We also evaluated the efficacy of HCV treatment in the IBD population.
  
  
  METHODS
  We conducted a retrospective review of all patients who underwent IFN-based treatment for HCV at the Mayo Clinic in Rochester, Minnesota from 2001 to 2012. Exacerbation of IBD was evaluated by clinical, endoscopic, and histologic parameters during antiviral therapy and the ensuing 12 months. Hematologic toxicity was assessed by levels of all 3 cell lineages at baseline and during therapy. Efficacy of antiviral treatment was assessed by serum levels of HCV RNA until 24 weeks after completion of therapy. We also conducted a detailed MEDLINE database search and reviewed the literature on this topic.
  
  
  RESULTS
  We identified 15 subjects with concomitant IBD (8 with ulcerative colitis and 7 with Crohn's disease). Only 1 patient experienced exacerbation of the disease during therapy; symptoms were controlled with mesalamine enemas. Another patient developed a flare shortly after completing antiviral therapy; symptoms returned spontaneously to baseline 2 weeks later. All subjects experienced an anticipated degree of pancytopenia while on IFN-based therapy. The rate of sustained virologic response was 67%. A concise review of available literature regarding the safety and efficacy of HCV treatment in IBD patients is also presented; although limited, the published data appear to support the safety of treatment with IFN in patients whose IBD is under control.
  
  
  CONCLUSIONS
  In conjunction with data from the literature, our findings indicate that the efficacy and safety of HCV therapy with IFN and ribavirin for patients with IBD are comparable to those of subjects without IBD.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Alina M
authors.initials: AM
authors.lastname: Allen
authors.forename: W Ray
authors.initials: WR
authors.lastname: Kim
authors.forename: Joseph
authors.initials: J
authors.lastname: Larson
authors.forename: Edward V
authors.initials: EV
authors.lastname: Loftus
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004724:Endoscopy; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006651:Histocytochemistry; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced* / Q000150:complications / Q000453:epidemiology*; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008910:Minnesota; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons
keywords: 6-MP; 6-TGN; 6-mercaptopurine; 6-thioguanine nucleotide; AZA; CD; Crohn's disease; HCV; IBD; IFN; Inflammation; PegIFN; SVR; UC; azathioprine; hepatitis C virus; inflammatory bowel disease; interferon; pegylated interferon; sustained virologic response; ulcerative colitis
references.citation: Int J Immunopharmacol. 1999 Apr;21(4):253-61
references.pmid: 10408633
references.citation: Nihon Shokakibyo Gakkai Zasshi. 2003 Jun;100(6):680-4
references.pmid: 12833862
references.citation: Rev Esp Enferm Dig. 1997 May;89(5):399-401
references.pmid: 9280430
references.citation: AIDS. 2006 Oct 3;20(15):1989-90
references.pmid: 16988527
references.citation: Aliment Pharmacol Ther. 2008 Oct 15;28(8):984-93
references.pmid: 18657132
references.citation: J Crohns Colitis. 2010 Oct;4(4):450-65
references.pmid: 21122543
references.citation: J Clin Invest. 2004 May;113(10):1490-7
references.pmid: 15146247
references.citation: Liver. 1996 Dec;16(6):390-9
references.pmid: 9021719
references.citation: Inflamm Bowel Dis. 2007 Sep;13(9):1189-90
references.pmid: 17427238
references.citation: Gastroenterology. 2002 Feb;122(2):593-4
references.pmid: 11845808
references.citation: J Crohns Colitis. 2012 Jun;6(5):626-7
references.pmid: 22398083
references.citation: Liver Transpl. 2011 Dec;17(12):1394-403
references.pmid: 21850690
references.citation: J Gastroenterol Hepatol. 2011 Dec;26(12):1709-16
references.pmid: 22097938
references.citation: Ital J Gastroenterol. 1995 Jan-Feb;27(1):3-4
references.pmid: 7795286
references.citation: Am J Gastroenterol. 2003 Jan;98(1):228-9
references.pmid: 12526978
references.citation: Gut. 2003 Dec;52(12):1728-33
references.pmid: 14633951
references.citation: J Antimicrob Chemother. 2006 Jan;57(1):8-13
references.pmid: 16293677
references.citation: Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29
references.pmid: 16918876
references.citation: Nihon Shokakibyo Gakkai Zasshi. 2008 Sep;105(9):1362-6
references.pmid: 18772577
references.citation: Inflamm Bowel Dis. 2011 Apr;17(4):1050
references.pmid: 20623698
references.citation: Aliment Pharmacol Ther. 2008 Sep 15;28(6):742-8
references.pmid: 19145730
references.citation: J Hepatol. 2012 Apr;56(4):973-83
references.pmid: 21963518
references.citation: Nihon Shokakibyo Gakkai Zasshi. 1995 Sep;92(9):1293-6
references.pmid: 7474487
references.citation: Dig Dis Sci. 2005 Aug;50(8):1533-4
references.pmid: 16110849
references.citation: Am J Gastroenterol. 2007 Jun;102(6):1333-4
references.pmid: 17531027
references.citation: Eur J Gastroenterol Hepatol. 1995 Jul;7(7):597-602
references.pmid: 8590152
references.citation: Dig Dis Sci. 2013 Apr;58(4):1149-56
references.pmid: 23179145
references.citation: Gastroenterol Clin Biol. 2005 Feb;29(2):193-6
references.pmid: 15795671
references.citation: J Hepatol. 2000 Apr;32(4):673-84
references.pmid: 10782918
references.citation: Intern Med. 1993 Apr;32(4):327-31
references.pmid: 8102914
references.citation: Gastroenterology. 1997 Mar;112(3):1017-21
references.pmid: 9041265
references.citation: Eur J Gastroenterol Hepatol. 2005 Nov;17(11):1243-5
references.pmid: 16215439
references.citation: Gut. 2005 Mar;54(3):438-9; author reply 439
references.pmid: 15710996
references.citation: Transplantation. 2004 Feb 27;77(4):562-7
references.pmid: 15084936
references.citation: Nihon Shokakibyo Gakkai Zasshi. 2001 Apr;98(4):399-404
references.pmid: 11400269
references.citation: N Engl J Med. 2009 Aug 6;361(6):580-93
references.pmid: 19625712
references.citation: Gut. 2006 Nov;55(11):1682-3
references.pmid: 17047132
references.citation: J Crohns Colitis. 2013 Jun;7(5):e194
references.pmid: 23219260
references.citation: Am J Gastroenterol. 2001 Jun;96(6):1807-15
references.pmid: 11419834
references.citation: Ann Rheum Dis. 2003 Nov;62(11):1078-82
references.pmid: 14583571
references.citation: J Hepatol. 2005 Mar;42(3):315-22
references.pmid: 15791697
references.citation: Eur J Gastroenterol Hepatol. 2001 Feb;13(2):191-2
references.pmid: 11246620
references.citation: J Hepatol. 2001 Jun;34(6):964-5
references.pmid: 11451187
references.citation: J Med Virol. 2008 Oct;80(10):1720-2
references.pmid: 18712814
references.citation: Digestion. 2006;73(4):210-4
references.pmid: 16883071
references.citation: Aliment Pharmacol Ther. 2005 Aug 1;22(3):209-15
references.pmid: 16091058